tbuckley/cabot-search huggingface dataset:
Abstract 11107: Impact of Annular Septal-Lateral Diameter on Mitral Leaflet Adaptation and Severity of Functional Mitral Regurgitation: Three-Dimensional Analysis with Computed Tomography
Authors: Kitae Kim, Shuichiro Kaji, Takeshi Kitai, Atsushi Kobori, Natsuhiko Ehara, Makoto Kinoshita, Atsushi Yamamuro, Tomoko Tani, Yutaka Furukawa
Journal: Circulation (2011)
Phase II trial of saracatinib in patients (pts) with ER/PR-negative metastatic breast cancer (MBC).
Authors: T. A. Traina, J. A. Sparano, J. Caravelli, S. Patil, A. Abbruzzi, R. Hawke, J. Bromberg, J. Nonemaker, L. Norton, C. Hudis
Journal: Journal of Clinical Oncology (2010)

1086 Background: Src activation is associated with a poor prognosis. Saracatinib is an oral, src inhibitor that blocks phosphorylation of downstream mediators of motility and invasion and inhibits metastases in vivo. The MTD and safety of saracatinib, including pulmonary toxicity, has been reported (Tabernero ASCO 2007). Based on preclinical efficacy, we tested the efficacy and safety of saracatinib in pts with ER/PR-negative(-) MBC. Methods: Eligible pts have ER(-), PR(-), MBC, and ≤1 prior chemotherapy (CRx) regimen for MBC. Pts with severe restrictive/obstructive lung disease were excluded. Therapy consists of saracatinib 175mg orally daily. Response assessed q12 weeks (wk). PFTs q2wk for first cycle, then q4wk. Primary endpoint is disease control rate (DCR)=CR+PR+SD>24wk. Secondary endpoints include RR, PFS, toxicity. Using a 2-stage design, 21 pts accrue to the first stage. If ≥2 pts have disease control, 20 pts will be accrued to the second stage. If >4 of 41 pts have CR, PR, or SD>24wk, saracatinib warrants further study. Correlative studies measure IL6 and CTCs. Results: Nine pts accrued. All are evaluable. Medians: age 52 (31- 85), ECOG PS 0 (0-1). Sites of MBC (#pts): viscera 8, chest wall/nodes 1. All pts are ER and PR <10%; HER2(+) 1 pt. Prior adjuvant CRx: 7pts. Median number of CRx regimens for MBC: 1 (0-1). After a median of 2 cycles (1-3), DCR=0, SD<24wk 3, POD 6. Treatment-related toxicity >10%: grade (Gr) 4: hypoxia 1; Gr 3: AST 2, adrenal insufficiency 1, hypophosphatemia 1, hyponatremia 1, hypokalemia 1, fatigue 1, leukopenia 1, lymphopenia 1; Gr 2 (>20%): neutropenia 2. One pt required dose reduction for elevated AST. One pt hospitalized during cycle 1 with fever, hypoxia, ARDS requiring intubation, and ICU care. Cultures(-); bronchoscopy cytology(-) for malignant cells. SAE attribution possibly related to saracatinib. Conclusions: Based on our experience in 9 pts, saracatinib did not demonstrate activity in ER/PR(-) MBC. We closed this trial early given the apparent risk:benefit ratio. Supported in part by NCI/CTEP and AstraZeneca. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca
Abstract 2562: Number of Consecutive Ectopic Beats of Non-Sustained Ventricular Tachycardia Episode Predicts Sudden Cardiac Death in Patients With Non-ST-Elevation ACS
Authors: Whedy Wang, Ewa Karwatowska-Prokopczuk, Dewan Zeng, Luiz Belardinelli
Journal: Circulation (2009)

INTRODUCTION: In pts with NSTEACS from MERLIN-TIMI 36, non-sustained ventricular tachycardia (NSVT) lasting ≥4 beats was associated with higher risk of sudden cardiac death (SCD), and ranolazine (R...
CASE OF TETANUS TREATED WITH ANTITOXIN AND D-TUBOCURARINE
Authors: W W PRYOR, D T SMITH
Journal: Annals of Internal Medicine (1950)

Case Reports1 April 1950CASE OF TETANUS TREATED WITH ANTITOXIN AND D-TUBOCURARINEWILLIAM W. PRYOR, M.D., DAVID T. SMITH, M.D., F.A.C.P.WILLIAM W. PRYOR, M.D.Search for more papers by this author, DAVID T. SMITH, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-32-4-728 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptPatients with tetanus are being treated more frequently with curare and curare-like drugs. Both optimistic and pessimistic reports have appeared in the literature.1, 2, 3, 4, 5, 6 In the following case some of the complications and dangers of this type of treatment are exemplified.CASE REPORTA 70 year old white male was admitted to Duke Hospital stating that he had been in good health until about 10 days previously, when he had developed a dull suboccipital headache with some stiffness of the neck. Within the next three days he began to have difficulty chewing and swallowing due to...Bibliography1. WeedPurvisWarkine MDFRD: d-Tubocurarine in wax and oil for control of muscle spasms in tetanus, J. A. M. A. 138: 1087, 1948. CrossrefMedlineGoogle Scholar2. Cole L: Tetanus treated with curare, Lancet 227: 475, 1934. CrossrefGoogle Scholar3. Florey HW: The treatment of tetanus, Lancet 227: 1036, 1934. CrossrefGoogle Scholar4. West R: Intravenous curarine in the treatment of tetanus, Lancet 230: 12, 1936. CrossrefGoogle Scholar5. Belfrage DH: Tubocurarin in tetanus, Lancet 253: 889, 1947. CrossrefGoogle Scholar6. McLeod M: Therapy of tetanus, North Carolina M. J. 8: 634, 1947. MedlineGoogle Scholar7. PerlsteinWeinglass MAA: Fatal effects of prolonged complete curarization, Am. J. Dis. Child. 67: 360, 1944. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Durham, North Carolina*Received for publication August 4, 1949.From the Departments of Medicine and Bacteriology, School of Medicine, Duke University, Durham, N. C. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byTETANUS IN CHILDHOOD. 1 April 1950Volume 32, Issue 4Page: 728-730KeywordsAntitoxinsBacteriologyDrugsHeadachesStiffnessSwallowingTetanus ePublished: 1 December 2008 Issue Published: 1 April 1950 PDF downloadLoading ...
Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM)
Authors: Paolo Anderlini, Rima M. Saliba, Celina Ledesma, Christina M Chancoco, Tamera Alexander, Amin Alousi, Chitra M. Hosing, Issa Khouri, Yago Nieto, Uday R Popat, Elizabeth J Shpall, Michelle A. Fanale, Yasuhiro Oki, Jorge E Romaguera, Sattva Neelapu, Anas Younes, Richard E Champlin
Journal: Blood (2013)
Oligoclonal reconstitution after high dose therapy with PBPCT in myeloma patients: Implications for assessment of remission status
Authors: Yasmina Bouko, Walter Feremans, Hartmut Goldschmidt, Jean Bourhis, Jose Luis Pico, Hildegarde Greinix, Jane J.F. Apperley, Diana Samson, Gosta Gahrton
Journal: Blood (2001)
Scurvy in the Presence of Thyrotoxicosis
Authors: R. H. Kampmeier
Journal: Annals of Internal Medicine (1931)

Article1 May 1931Scurvy in the Presence of ThyrotoxicosisR. H. KAMPMEIER, M.D., F.A.C.P.R. H. KAMPMEIER, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-4-11-1469 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptA search of the literature available to me has failed to reveal a case report in which this peculiar association of diseases occurred.The patient whose case is reported below showed a group of symptoms and signs which confused the diagnosis so that, though scurvy was considered at once, the thyrotoxicosis was not appreciated at first.Case ReportCase Report—J. T., a Spaniard aged 52, barber by occupation, entered the Pueblo Clinic on April 5, 1930, and was referred to me by Dr. H. A. Black.Chief Complaint—Diarrhea, fever, and weakness.Present Illness—In December, 1929, the patient had had a... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Pueblo, Colo.*From the Pueblo Clinic, Pueblo, Colo. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1931Volume 4, Issue 11Page: 1469-1471KeywordsFeversSigns and symptoms Issue Published: 1 May 1931 PDF downloadLoading ...
Abstract 1383: Mitochondrial Tert Enhances Mitochondria Functions In Vivo by Protecting Mitochondrial DNA Integrity from Oxidative Damage
Authors: Nicole Buechner, Stefan Dröse, Sascha Jakob, Ulrich Brandt, Joachim Altschmied, Judith Haendeler
Journal: Circulation (2008)

Mitochondria are essential for respiration and oxidative phosphorylation. Mitochondrial dysfunction due to aging processes is involved in pathologies and pathogenesis of a series of cardiovascular disorders. New results accumulate showing that the enzyme telomerase with its catalytic subunit telomerase reverse transcriptase (TERT) has a beneficial effect on heart functions. The benefit of short-term running of mice for heart function is dependent on TERT expression. TERT can translocate into the mitochondria and mitochondrial TERT (mtTERT) is protective against stress induced stimuli and binds to mitochondrial DNA (mtDNA). Because mtDNA is highly susceptible to damage produced by reactive oxygen species (ROS) which are generated in close proximity to the respiratory chain, the aim of this study was to determine the functions of mtTERT in vivo and in vitro. Therefore, mitochondria from hearts of adult, 2nd generation TERT-deficient mice (TERT −/−) and wt littermates were isolated and state 3 respiration was measured. Strikingly mitochondria from TERT −/− revealed a significantly lower state 3 respiration (TERTwt: 987 +/− 72 pmol/s*mg vs. TERT−/−: 774 +/− 38 pmol/s*mg, p&lt;0.05, n=5). These results demonstrated that TERT −/− mice have a so far undiscovered heart phenotype. In contrast mitochondria isolated from liver tissues did not show any differences. To get further insights in the molecular mechanisms, we reduced endogenous TERT levels by shRNA and measured mitochondrial reactive oxygen species (mtROS). mtROS were increased after ablation of TERT (scrambled: 4.98 +/− 1.1 % gated vs. shTERT: 2.03 +/−0.7 % gated, p&lt;0.05, n=4). We next determined mtDNA deletions, which are caused by mtROS. Semiquantitative realtime PCR of mtDNA deletions revealed that mtTERT protects mtDNA from oxidative damage. To analyze whether mitochondrial integrity is required to protect from apoptosis, vectors with mitochondrially targeted TERT (mitoTERT) and wildtype TERT (wtTERT) were transfected and apoptosis was measured. mitoTERT showed the most prominent protective effect on H2O2 induced apoptosis. In conclusion, mtTERT has a protective role in mitochondria by importantly contributing to mtDNA integrity and thereby enhancing respiration capacity of the heart.
LP18 : Obeticholic acid for NASH: benefits in a high risk subgroup and the effects of concomitant statin use
Authors: B. Neuschwander-Tetri, A. Sanyal, R. Loomba, N. Chalasani, K. Kowdley, M. Abdelmalek, E. Brunt, D. Shapiro
Journal: Journal of Hepatology (2015)
Generation and Performance of Outcome Indicators in Liver Disease: The Value Based Medicine in Hepatology Study (VBMH)
Authors: M. Rota, S. Okolicsanyi, A. Ciaccio, M. Gemma, M. Gentiluomo, A. Grisolia, P. A. Cortesi, L. Scalone, L. G. Mantovani, G. Cesana, Patrizia Pontisso, M. U. Mondelli, G. Marchesini, Luca Fabris, V. Mazzaferro, Patrizia Burra, M. Colledan, S. Fagiuoli, L. S. Belli, M. Strazzabosco
Journal: Hepatology (2013)
Abstract 19379: The Relationship Between Dietary Magnesium Intake and Heart Failure Hospitalizations in African American Adults: The Jackson Heart Study
Authors: Tracey H Taveira, Danielle Ouellette, Alev Gulum, Gaurav Choudhary, Charles B Eaton, Wen Chih H Wu
Journal: Circulation (2014)

Background: Low serum and dietary magnesium (Mg) intake are established risk factors for stroke, coronary disease, hypertension and type 2 diabetes mellitus, but little is known on the relationship between Mg intake and heart failure (HF). African Americans are known to have a low dietary Mg intake and have a high risk of HF compared to the general population; thus, an ideal group to study this relationship. We hypothesize that dietary Mg relates to HF hospitalization in African Americans.

Methods: A cohort study was conducted on 5,133 participants from Jackson Heart Study, recruited during 2000-2004, in Jackson (MS), who completed a 61-item semi-quantitative food frequency questionnaire. The main outcome was hospitalization for HF during 2005-2010. We related different cutoffs of dietary Mg intake (overall, mean, Recommended Daily Allowance [RDA] for men and RDA for women) with HF hospitalization using Cox proportional hazards modeling adjusting for potential confounding. Since HF hospitalization risk may vary by systolic function, we also conducted subgroup analyses by ejection fraction. Given gender differences in RDA cutoffs for Mg intake, we also tested for interaction by gender.

Results: The study cohort had a mean age of 55.3 (SD 12.8 yrs), of which 63.4% were women, 21.6% had diabetes, 62.7% hypertension, and 10.6% had coronary or cerebrovascular disease. Cox modeling showed Mg Intake above mean (308mg/day) or RDA levels for women (310mg/day) to be related to decreased hazards of HF hospitalization, adjusted Hazard Ratio 0.51 (95% CI 0.30-0.85) and 0.49 (95% CI 0.29-0.83), respectively; but only in subjects with ejection fraction (EF) ≤55% (Table). Test for interaction by gender was not significant.

Conclusions: Dietary Mg intake was related to HF hospitalization only in African Americans with EF ≤55%. Further studies exploring the mechanisms that underlie this relationship may be warranted.

   ![][1]  [1]: /embed/graphic-1.gif
The role of IGF-1R in EGFR TKI resistance in NSCLC using IHC and AQUA technology.
Authors: Y. Kato, C. Mascaux, M. W. Wynes, B. Reyna Asuncion, C. Tran, K. Yoshida, J. Matsubayashi, E. Nakajima, T. Ohira, T. Nagao, K. Furukawa, N. Ikeda, F. R. Hirsch
Journal: Journal of Clinical Oncology (2011)

10556 Background: Epidermal growth factor receptor (EGFR) mutations predict benefit from EGFR tyrosine kinase inhibitors (TKI) in non-small cell lung cancer (NSCLC), however, only 70-80% will respond. Ultimately, all patients (pts) develop drug resistance. The insulin-like growth factor-1 (IGF-1) pathway may have a role in EGFR TKI resistance. We assessed IGF-1R protein expression and its association to progressive disease (PD) and outcome in EGFR TKI treated NSCLC pts using immunohistochemistry (IHC) and automated quantitative fluorescence analysis technology (AQUA). Methods: IGF-1R protein expression (Ventana Medical Systems, Inc, Tucson, AZ) was analyzed in 98 and 70/98 gefitinib-treated Japanese NSCLC pts, respectively, with IHC and AQUA (HistoRx Inc, New Haven, CT). IHC scoring was performed with the H-scoring method evaluating membrane or cytoplasm only and membrane + cytoplasm. Results: IGF-1R expression was significantly higher in pts with PD vs disease control (CR+PR+SD) using any method of assessment. Using ROC curve analyses, the best discrimination of PD vs DC was obtained with IHC scoring of membrane + cytoplasm and a cutoff of 165, with an accuracy of 72%, sensitivity and specificity of 68% and 73% with an area under the curve of 0.75 (p=0.0006). Overall survival (OS) from gefitinib was worse in pts with high IGF-1R using cutoff 165 (median 14.7 vs 29.1 months (ms), p=0.0175) or by an arbitrary cutoff of 40 (16.2 vs 43.6 ms, p=0.0138). Progression free survival (PFS) was shorter in high IGF-1R pts with a 165 (4.6 vs 12.0 ms, p=0.0065) or 40 cutoff (8.7 vs 28.7 ms, p=0.0296). Prediction of PD and shorter PFS by high IGF-1R IHC membrane + cytoplasm scoring remained significant in the adenocarcinomas (n=78) and EGFR mutations (n=49) subgroups. High IGF-1R expression evaluated by AQUA was also predictive of PD (p=0.033) and shorter PFS (p=0.0496) in a 70 pt subset. Conclusions: High IGF-1R protein expression, evaluated both by IHC and AQUA, predicted primary resistance to gefitinib therapy in NSCLC and was associated with worse OS and shorter PFS. Thus, IGF-1R protein expression appears to be a clinically relevant biomarker to identify NSCLC pts with intrinsic EGFR TKI resistance, even in pts having EGFR mutations.
Abstract P1-10-05: A cost utility analysis from a Chinese health care perspective of Nab-paclitaxel or docetaxel, both as alternatives to solvent-based paclitaxel in metastatic breast cancer (MBC)
Authors: George Dranitsaris, Bo Yu, Jennifer King, Adams Zhang, Satyn Kaura, Zhai Qing
Journal: Cancer Research (2015)

Abstract Background: Paclitaxel and docetaxel are commonly used for the treatment of MBC in China. However, one important drawback, particularly with docetaxel, is the potential for dose-limiting toxicity. To improve the side effect profile and efficacy of paclitaxel, an albumin-bound formulation (nab-paclitaxel) is currently available in China (Abraxane®). To provide health economic data for China, a cost utility analysis comparing nab-paclitaxel to docetaxel, both as alternatives to paclitaxel was conducted. Methods: Clinical data was obtained from a meta analysis of randomized trials comparing either nab-paclitaxel (260 mg/m2 q3wk) or branded docetaxel (100 mg/m2 q3wk) to solvent-based branded paclitaxel (175 mg/m2 q3wk). Health care resource use for the delivery of chemotherapy and the management of grade 3/4 toxicity was collected from a time and motion study in three Chinese cancer centers, from a survey of clinicians and from the oncology literature. Using the Time Trade-off technique, treatment preferences and utility estimates were obtained from interviewing 28 cancer patients from two centres in China. All costs were reported in 2014 $U.S. Results: Nab-paclitaxel had the most favourable safety profile characterized with the lowest incidence of grade 3/4 neutropenia, febrile neutropenia, anemia, emesis and stomatitis. This translated to lower costs for managing the grade 3/4 side effects of nab-paclitaxel relative to both docetaxel and paclitaxel ($21 vs. $166 vs. $81) In the preference assessment, 22 of 28 (78.6%) patients selected nab-paclitaxel as their preferred agent. As an alternative to paclitaxel, the incremental cost per quality adjusted life year (QALY) gained was determined to be more favourable with nab-paclitaxel than docetaxel ($57,900 vs. $130,600). Conclusions: Nab-paclitaxel is an economically attractive alternative to both paclitaxel and docetaxel in MBC patients, providing a substantially lower cost per QALY. Additionally in the patient preference survey, the majority of patients surveyed selected nab-paclitaxel as their preferred agent. Citation Format: George Dranitsaris, Bo Yu, Jennifer King, Adams Zhang, Satyn Kaura, Zhai Qing. A cost utility analysis from a Chinese health care perspective of Nab-paclitaxel or docetaxel, both as alternatives to solvent-based paclitaxel in metastatic breast cancer (MBC) [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P1-10-05.
Abstract 060: Long-term Effectiveness of a Color-coded Food Labeling Intervention in Promoting Healthy Choices
Authors: Anne N Thorndike, Jason Riis, Lillian Sonnenberg, Douglas E Levy
Journal: Circulation (2013)

Background: To reduce obesity, food labeling interventions must produce sustained changes in population eating behaviors, but the long-term effectiveness of food labeling is unknown. Methods: We pr...
Abstract 15336: Morphine Attenuates Mitochondria Oxidative Stress by Modulating Complex I Activity Upon Reperfusion Via Mitochondrial Src Tyrosine Kinase and Reduces Infarct Size in Rat Hearts
Authors: Jin Huh, Juan Zhou, David A Zvara, Zhelong Xu
Journal: Circulation (2011)

Although morphine has been demonstrated to protect the heart from ischemia/reperfusion injury through various signaling mechanisms, the signaling events occurring within mitochondria that mediate m...
Pre-Clinical Activity of Adct-301, a Novel Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Authors: Michael J Flynn, Patrick van Berkel, Francesca Zammarchi, Jean-Noel Levy, Arnaud Tiberghien, Luke A Masterson, François D'Hooge, Lauren Adams, David G Williams, Philip W Howard, John A Hartley
Journal: Blood (2014)
Abstract 8093: Inorganic Nitrite Induces Second-Window Preconditioning in Healthy Volunteers
Authors: Julian O Ormerod, Jonathan D Evans, Hussain Contractor, Raj Kharbanda, Michael P Frenneaux, Houman Ashrafian
Journal: Circulation (2011)

Background Inorganic nitrite has been shown to induce preconditioning in a variety of animal and tissue models. Work from our group has shown that nitrite can induce periconditioning in a human model of ischemia-reperfusion injury, which is influenced by ALDH2 genotype. We investigated whether systemic inorganic nitrite infusion, given 24 hours before the onset of ischemia, protects human forearm endothelium from ischemia-reperfusion injury in unselected healthy volunteers. Methods 12 healthy volunteers were randomised to 2 groups. Inorganic nitrite or saline placebo was given intravenously at a dose of 1 mcg/kg/min for 10 minutes, 24 hours before the onset of studies. Venous occlusion plethysmography, using escalating doses of intra-arterial acetylcholine, was used to measure forearm endothelial function before and 15 minutes after 20 minutes of total forearm ischemia. Results Ischemia-reperfusion injury caused significant endothelial dysfunction in those that had received a placebo infusion (n=5, p&lt;0.05). Conversely, the group that received systemic nitrite 24 hours before study were protected from IR injury (p=0.78 for a difference pre- and post-ischemia). Discussion This study shows, for the first time in man, that a simple cost-effective intervention has potential to prevent injury in situations where significant ischemia-reperfusion injury is predictable, such as in cardiac surgery. More speculatively, this mechanism may be involved in the health benefits of a diet containing nitrite-rich green leafy vegetables. This result invites further study in the form of clinical trials.